Summit Therapeutics SMMT Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's business segments — R&D?
- Summit Therapeutics (SMMT) reported business segments — R&D of $90.2M in Q1 2026.
- How has Summit Therapeutics's business segments — R&D changed year-over-year?
- Summit Therapeutics's business segments — R&D increased by 148.0% year-over-year, from $36.36M to $90.2M.
- What does business segments — R&D mean?
- The total spending on scientific research and clinical development projects within this business segment.
- How do you interpret business segments — R&D?
- An increase typically signals a ramp-up in clinical trial activity or pipeline expansion, while a decrease may indicate project completion or cost-cutting measures.
- How does business segments — R&D compare across companies?
- Standard across biopharmaceutical companies; peers typically report this as a primary operating expense line item.